1 Free Consult Schedule a video call with one of our providers
T2DM patients have low bone mineral density and increased fracture risk, especially hip and vertebral fractures ( GLP-1 is produced by the post-translational processing of the glucagon gene in intestinal endocrine cells ( Our study also demonstrated that GLP-RAs could significantly reduce the risk of osteoporosis in T2DM patients, consistent with the find with Liraglutide
On the other hand, the side effects of CJC-1295 are generally mild and transient, with the most common being irritation at the injection site, headache, flushing, and dizziness
FDA approves Ozempic to reduce the risk of kidney disease worsening, kidney failure and death due to CV disease in adults with type 2 diabetes and CKD Novo Nordisk Novo Nordisk announced that the FDA has approved Ozempic (semaglutide injection) to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD)